Table 5.
Dynamics in cGFAP concentration during 14 months of nusinersen treatment.
| 14‐month analysis | |||||
|---|---|---|---|---|---|
| N | Median (IQR) | Difference versus baseline | p value | ||
| Median (IQR) | (%) | ||||
| cGFAP [ng/mL] | 58 | 0.5838 (0.4144–0.8982) | −0.0488 (−0.1199–0.1049) | −7.4 | 0.158 |
| HFMSE increase | 21 | 0.4725 (0.4104–0.7337) | −0.0700 (−0.2275 to −0.0017) | −11.6 | 0.018 |
| HFMSE decrease | 6 | 0.8858 (0.7337–1.2268) | −0.0371 (−0.2468 to 0.5370) | −4.0 | 0.753 |
cGFAP, glial fibrillary acidic protein concentration in cerebrospinal fluid; HFMSE, Hammersmith Functional Motor Scale Expanded; IQR, interquartile range; p value calculated by Wilcoxon signed‐rank test, significant values are marked in bold.